NASDAQ:MRUS - Merus Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.90 +0.10 (+0.78 %)
(As of 01/20/2019 12:12 PM ET)
Previous Close$12.90
Today's Range$12.40 - $13.30
52-Week Range$11.00 - $26.74
Volume58,958 shs
Average Volume33,400 shs
Market Capitalization$293.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.36 million
Book Value$2.79 per share

Profitability

Net Income$-82,610,000.00
Net Margins-140.49%

Miscellaneous

Employees83
Market Cap$293.49 million
OptionableNot Optionable

Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

1 brokerages have issued 12 month target prices for Merus' stock. Their predictions range from $34.00 to $34.00. On average, they anticipate Merus' share price to reach $34.00 in the next year. This suggests a possible upside of 163.6% from the stock's current price. View Analyst Price Targets for Merus.

What is the consensus analysts' recommendation for Merus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Has Merus been receiving favorable news coverage?

News stories about MRUS stock have been trending extremely positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merus earned a news impact score of 4.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of Merus' key competitors?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg, Pres, CEO & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Mr. John J. Crowley, CFO & Exec. VP (Age 45)
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $12.90.

How big of a company is Merus?

Merus has a market capitalization of $293.49 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 83 workers across the globe.

What is Merus' official website?

The official website for Merus is http://www.merus.nl.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel